Enhancing glioma treatment with 3D scaffolds laden with upconversion nanoparticles and temozolomide in orthotopic mouse model

Targeted drug delivery for primary brain tumors, particularly gliomas, is currently a promising approach to reduce patient relapse rates. The use of substitutable scaffolds, which enable the sustained release of clinically relevant doses of anticancer medications, offers the potential to decrease th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in chemistry Jg. 12; S. 1445664
Hauptverfasser: Mishchenko, Tatiana A., Klimenko, Maria O., Guryev, Evgenii L., Savelyev, Alexander G., Krysko, Dmitri V., Gudkov, Sergey V., Khaydukov, Evgeny V., Zvyagin, Andrei V., Vedunova, Maria V.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 21.10.2024
Schlagworte:
Chemistry
GL261 cells
hyaluronic acid hydrogels
orthotopic glioma model
temozolomide
upconversion nanoparticles
temozolomide
orthotopic glioma model
hyaluronic acid hydrogels
upconversion nanoparticles
GL261 cells
ISSN:2296-2646, 2296-2646
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Targeted drug delivery for primary brain tumors, particularly gliomas, is currently a promising approach to reduce patient relapse rates. The use of substitutable scaffolds, which enable the sustained release of clinically relevant doses of anticancer medications, offers the potential to decrease the toxic burden on the patient’s organism while also enhancing their quality of life and overall survival. Upconversion nanoparticles (UCNPs) are being actively explored as promising agents for detection and monitoring of tumor growth, and as therapeutic agents that can provide isolated therapeutic effects and enhance standard chemotherapy. Our study is focused on the feasibility of constructing scaffolds using methacrylated hyaluronic acid with additional impregnation of UCNPs and the chemotherapeutic drug temozolomide (TMZ) for glioma treatment. The designed scaffolds have been demonstrated their efficacy as a drug and UCNPs delivery system for gliomas. Using the aggressive orthotopic glioma model in vivo , it was found that the scaffolds possess the capacity to ameliorate neurological disorders in mice. Moreover, upon intracranial co-implantation of the scaffolds and glioma cells, the constructs disintegrate into distinct segments, augmenting the release of UCNPs into the surrounding tissue and concurrently reducing postoperative damage to brain tissue. The use of TMZ in the scaffold composition contributed to restraining glioma development and the reduction of tumor invasiveness. Our findings unveil promising prospects for the application of photopolymerizable biocompatible scaffolds in the realm of neuro-oncology.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Rozhina Elvira, Kazan Federal University, Russia
Vad Pérez, Mexican Social Security Institute, Mexico
Edited by: Kelong Fan, Chinese Academy of Sciences (CAS), China
Mars Sharapov, Institute of Cell Biophysics (RAS), Russia
These authors have contributed equally to this work and share last authorship
ISSN:2296-2646
2296-2646
DOI:10.3389/fchem.2024.1445664